|
Audience:
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by an
educational grant from
Bristol Myers Squibb
Description:
Psoriasis is a complex, chronic, immune-mediated inflammatory
disease that affects approximately 7 million of the population in
the United States. Psoriasis is a periodic flare-up of sharply
defined red patches, covered by a silvery, flaky surface. The main
disease activity leading to psoriasis occurs in the epidermis, the
top five layers of the skin. The disease most commonly appears on
the skin of the scalp, elbow, knees, and lumbosacral areas of the
body. Many of the patients are not receiving the appropriate
treatment discussed in the current guidelines and standards of care.
Psoriasis is a complex disease to manage, but the goal should be a
patient-centered treatment that reduces disease burden, improves
quality-of-life, and addresses the risks of systemic complications
and comorbid conditions. The under diagnosis and treatment of
psoriasis continues to be a serious concern. It is for these reasons
that there needs to be continuing education that addresses the
treatment gaps and challenges in the diagnosis, treatment, and
management of psoriasis.
Upon completion of this
activity, participants will be able to:
-
Analyze the latest guidelines and the pathogenesis of psoriasis
while exploring the different options in the treatment paradigm
-
Discuss the key efficacy and safety data of novel targeted
therapies for patients with psoriasis to optimize long-term
outcomes based on their mechanisms of action
-
Compare and contrast current and emerging treatments based on
clinical data and the latest clinical evidence, including a
close look at TYK2 inhibitors
-
Apply strategies to overcome poor adherence and address
patients’ barriers to care for novel treatments for plaque
psoriasis
-
Identify managed care strategies to ensure balance between
cost-effectiveness and best practices to optimize outcomes for
patients with psoriasis
Faculty:
Paul Yamauchi, MD, PhD
President, Dermatology Institute & Skin Care Center, Inc.
Clinical Assistant Professor of Dermatology
David Geffen School of Medicine at UCLA
paulyamauchi@yahoo.com
Disclosure Information:
As accredited providers, NAMCP and AAMCN must ensure balance,
independence, objectivity, and scientific rigor in all of their
activities. All faculty participating in this activity are required
to disclose to NAMCP/AAMCN any financial relationships with
ineligible companies. NAMCP/AAMCN in turn discloses all relevant
financial conflicts to the learners. NAMCP/AAMCN disclosure policy
adheres to The Standards for Integrity and Independence in
Accredited Continuing Education. All relevant conflicts of interest
have been mitigated prior to the commencement of the activity. See
below for conflicts of interest.
Disclosures (Relevant Financial Relationships with Ineligible
Companies in the Last 24 Months):
Dr. Yamauchi has served as a consultant for Abbvie, Amgen, Arcutis,
BMS, Boerhinger Ingelheim, Dermvant, EPI Health, Evelo, Incyte,
Janssen, Leo, Lilly, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma,
and UCB. He has served as a speaker for Abbvie, Amgen, BMS, EPI
Health, Incyte, Janssen, Leo, Lilly, Pfizer, Regeneron, Sanofi, Sun
Pharma, and UCB. He has received grant/research support from Abbvie,
Amgen, Arcutis, BMS, Boerhinger Ingelheim, Dermavant Galderma,
Incyte, Janssen, Leo, Lilly, Novartis, Pfizer, Regeneron, Sun Pharma,
and UCB. All relevant financial relationships have been mitigated.
Planning Committee Disclosures (Relevant Financial Relationships
with Ineligible Companies in the Last 24 Months):
Bill Williams, MD has no relevant financial relationship with an
ineligible company to disclose.
Jeremy Williams has no relevant financial relationship with an
ineligible company to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationship
with an ineligible company to disclose.
NAMCP and/or the presenter has copyright or has received permissions
for use of materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring
material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
requirements.
NAMCP and/or this website do not provide medical advice, diagnosis,
or treatment. NAMCP does not endorse or imply endorsement of the
content on any linked website. This website is to be used as an
informational resource. With any health-related concern, consult
with your physician or healthcare professional.
This activity is supported by an educational grant from
Bristol Myers Squibb
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
professional.
Click Here To Continue |